跳至主要内容
临床试验/EUCTR2008-006014-20-IT
EUCTR2008-006014-20-IT进行中(未招募)不适用

Effects of the dose of erythropoiesis stimulating agents on cardiac-cerebrovascular outcomes and quality of life in hemodialysis patients. The DOSe of Erythropoietins (DOSE) trial. - C.E. DOSE

CONSORZIO MARIO NEGRI SUD0 个研究点开始时间: 2008年11月21日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Male or female, age>=18, with end stage kidney disease and anemia, treated with hemodialysis for renal replacement therapy, with no contraindications to erythropoietin stimulating agents (ESA) or already treated with ESA
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients with Hb levels >10 g/dl without ESA

研究者

发起方
CONSORZIO MARIO NEGRI SUD

相似试验